Drugs / EMIDURDAR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04652206 | Oct 2020 → Mar 2022 | pancreatic adenocarcinoma | Scandion Oncology A/S | Unknown | No outcome recorded |
| Phase 1/2 | NCT04247256 | May 2020 → Jun 2022 | colorectal cancer | Scandion Oncology A/S | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 28
| Date | Issuer | Release |
|---|---|---|
| 2025-01-13 | Scandion Oncology A/S | Results Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer scandiononcology.com ↗
Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to revert drug resistance, announces final data from CORIST trial part 1, 2 and 3. |
| 2024-08-16 | Scandion Oncology A/S | Results Scandion Oncology achieves Maximum Tolerated Dose for CORIST part 3 scandiononcology.com ↗
Scandion Oncology (Scandion), an innovative drug efflux pump inhibition company using biomodulation capabilities to revert drug resistance, today announced topline data for the CORIST part 3 continuation trial and that the company established the maximum tolerated dose (MTD) of SCO-101 in combination with the chemotherapy FOLFIRI in colorectal cancer patients. |
| 2024-05-13 | Scandion Oncology A/S | Results Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101 scandiononcology.com ↗
Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, today announces final data from the PANTAX phase Ib trial confirming the good safety profile of SCO-101 and showing good signs of efficacy in hard-to-treat pancreatic cancer. |
| 2024-03-21 | Scandion Oncology A/S | Results Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival scandiononcology.com ↗
A novel potential biomarker – the UGT1A1 genotype – was positively associated to longer progression free survival (PFS) and overall survival (OS). |
| 2024-03-07 | Scandion Oncology A/S | Results Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial scandiononcology.com ↗
Scandion Oncology (Scandion), a biotech company developing first-in-class medicines bio-modulating ABCG2 and UGT1A1 to treat cancers resistant to current treatment options, today announced the second confirmed partial response in the last cohort in the ongoing Part 3 of the CORIST Phase IIa colorectal cancer trial with Scandion’s lead compound SCO-101. |
| 2024-01-31 | Scandion Oncology A/S | Results Scandion Oncology reports positive topline Phase IIa data from the CORIST Part 3 trial scandiononcology.com ↗
Scandion Oncology (Scandion), a biotech company developing first-in-class medicines bio-modulating ABCG2 and UGT1A1 to treat cancers resistant to current treatment options, announced positive topline results from the ongoing Part 3 of the CORIST phase IIa colorectal cancer trial with Scandion’s lead compound SCO-101. |
| 2024-01-05 | Scandion Oncology A/S | Regulatory Scandion Oncology receives Notice of Allowance for patent to enhance US patent exclusivity on SCO-101 scandiononcology.com ↗
Scandion has received a Notice of Allowance from the United States Patent and Trademark Office meaning a patent will officially be granted following payment of the issue fee, which will be done shortly. |
| 2023-12-15 | Scandion Oncology A/S | Results Scandion Oncology identifies potentially effective treatment of gastric cancer scandiononcology.com ↗ |
| 2023-11-21 | Scandion Oncology A/S | Results Final data from the Phase IIa open-label CORIST part 2 trial shows impressive median Overall Survival of 10.4 months scandiononcology.com ↗
Patients in part 2 of the CORIST trial had median Overall Survival (OS) of 10.4 months |
| 2023-10-16 | Scandion Oncology A/S | Results Phase Ib PANTAX trial is successfully completed and establishes the maximal tolerated dose with positive safety profile and pharmacokinetic data. scandiononcology.com ↗
The data confirms that SCO-101 is safe and well-tolerated in this indication and combination, thereby also supporting the general profile of SCO-101 as well-tolerated in combination with different chemotherapies in patients with late-stage disease. |
| 2023-03-31 | Scandion Oncology A/S | Results Scandion Oncology successfully completes the dose finding with lead compound SCO-101 in advanced pancreatic cancer patients (PANTAX phase Ib trial) scandiononcology.com ↗
The trial’s primary endpoint was achieved, establishing the maximum tolerated dose of SCO-101 in combination with the standard chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. |
| 2022-09-30 | Scandion Oncology A/S | Results Scandion Oncology announce topline results from part 2 of the CORIST phase II trial scandiononcology.com ↗
Data from part 2 of the trial confirm the safety and tolerability of SCO-101. |
| 2022-08-19 | Scandion Oncology A/S | Regulatory Scandion Oncology receives approvals for next parts of the CORIST trial scandiononcology.com ↗
The development of SCO-101 will continue as planned with expansion of the CORIST trial expected to commence during the third quarter of 2022. |
| 2022-08-17 | Scandion Oncology A/S | Results Scandion Oncology extends PANTAX trial due to better-than-expected tolerability of SCO-101 scandiononcology.com ↗
Good tolerability allows for continued dose escalation in the dose-finding PANTAX phase 1b-trial with SCO-101 as combination therapy in pancreatic cancer. |
| 2021-09-02 | Alligator Bioscience AB | Results Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy alligatorbioscience.se ↗
After the final data has been evaluated, the joint feasibility study have reached all goals of the cooperation and the companies have now concluded the collaboration. |
| 2021-08-27 | Scandion Oncology A/S | Regulatory Scandion Oncology receives German trial approval for PANTAX Ib study scandiononcology.com ↗
Scandion Oncology A/S today announced that the company has obtained approval from the German regulatory authorities to initiate clinical trials in Germany with SCO-101 in the PANTAX Ib study. |
| 2021-08-25 | Scandion Oncology A/S | Regulatory First US patent granted to Scandion Oncology on combination treatment with its candidate drug SCO-101 scandiononcology.com ↗
Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that the US Patent and Trademark Office (USPTO) will grant the company’s patent US11,103,481 directed to the use of SCO-101, on August 31, 2021. |
| 2021-06-30 | Scandion Oncology A/S | Results Scandion Oncology A/S and Alligator Bioscience AB present promising preclinical data scandiononcology.com ↗
Scandion Oncology (Nasdaq Stockholm: SCOL) and Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced promising preclinical data from their ongoing collaboration exploring the anti-tumor effects on drug resistant cancer by combining Scandion Oncology’s drug candidate SCO-101 and Alligator Bioscience’s candidate drug mitazalimab. |
| 2021-06-30 | Alligator Bioscience AB | Results Alligator Bioscience AB and Scandion Oncology A/S present promising preclinical data alligatorbioscience.se ↗
Importantly, the current data indicate that the anti-tumor effect of SCO-101, mitazalimab and FOLFIRINOX is even more potent than mitazalimab and FOLFIRINOX. |
| 2021-06-24 | Scandion Oncology A/S | Results Scandion Oncology reports positive interim results from the CORIST Phase II study scandiononcology.com ↗
Scandion Oncology A/S today reports positive results from the dose-finding part 1 of the CORIST Phase II study. |
| 2020-09-28 | Scandion Oncology A/S | Regulatory Scandion Oncology receives final approval from the Danish Medicines Agency and Ethical Committee for start of a clinical trial in patients with pancreatic cancer scandiononcology.com ↗
Scandion Oncology A/S (“Scandion Oncology”) today announces that the company has received final approval from the Danish Medicines Agency and Ethical Committee to initiate a clinical trial with the drug candidate SCO-101 in combination with first line chemotherapy in patients with inoperable or metastatic pancreatic cancer. |
| 2020-07-31 | Scandion Oncology A/S | Results Scandion Oncology drug SCO-101 potentiates the effect of chemotherapy in the first cohort of patients with chemo-resistant metastatic colorectal cancer scandiononcology.com ↗
The main result is that 150 mg daily oral SCO-101 potentiates the effects of chemotherapy (FOLFIRI). |
| 2020-07-11 | Scandion Oncology A/S | Results Scandion Oncology announces that the results of the 4 SCO-101 clinical phase I trials have been published in the journal “Basic & Clinical Pharmacology & Toxocology”. scandiononcology.com ↗
Scandion Oncology A/S (“Scandion Oncology”) announces that the results from the 4 SCO-101 phase I clinical trials have been published (https://doi.org/10.1111/bcpt.13466) in the International peer-reviewed journal” Basic & Clinical Pharmacology & Toxicology”. |
| 2020-03-25 | Scandion Oncology A/S | Results SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells scandiononcology.com ↗
Based on modelling of preclinical data with docetaxel resistant cancer cells, Scandion Oncology has published that SCO-101 significantly increases the potency of docetaxel (docetaxel belongs to the group of taxane chemotherapy). |
| 2019-12-23 | Scandion Oncology A/S | Regulatory Scandion Oncology obtains approval from the Ethics Committee on Clinical Application for SCO-101 in patients with drug-resistant metastatic colorectal cancer scandiononcology.com ↗
Scandion Oncology A/S ("Scandion Oncology") today announces that the company has received approval from the Ethics Committee regarding its first clinical trial for SCO-101 at hospitals in Denmark. |
| 2019-11-29 | Scandion Oncology A/S | Regulatory Scandion Oncology receives final approval from the Danish Medicines Agency for start of clinical Phase II trial in patients with drug resistant metastatic colorectal cancer scandiononcology.com ↗
Scandion Oncology A/S (“Scandion Oncology”) today announces that the company has received final approval from the Danish Medicines Agency for start of a clinical Phase II trial with the drug candidate SCO-101 in combination with chemotherapy in patients with drug resistant metastatic colorectal cancer. |
| 2019-10-14 | Scandion Oncology A/S | Regulatory Scandion Oncology A/S receives EU-patent for SCO-101 scandiononcology.com ↗
Scandion Oncology A/S (“Scandion Oncology”) today announces that the European Patent Office (“EPO”) has granted the company’s patent application for SCO-101 when combined with chemotherapy. |
| 2019-05-21 | Scandion Oncology A/S | Regulatory SCANDION ONCOLOGY A/S obtains “Intention to Grant” notice for SCO-101 from the European Patent Office (EPO) scandiononcology.com ↗
SCANDION ONCOLOGY A/S is pleased to announce that the company has received an “Intention to Grant” notice from the EPO regarding its European patent application 17726573.3, which includes SCO-101 in combination with specific topoisomerase I inhibitors to treat various cancers. |
All press releases naming this drug 43 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMIDURDAR | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314516 ↗ |
| Known as | Endovion | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314516 ↗ |
| Known as | NS-3728 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314516 ↗ |
| Known as | SCO-101 | “SCO-101 is an oral compound that may counteract chemo-resistance by interacting with SRPK1, ABCG2 drug transporter, and liver enzyme UGT1A1.” PMID 40272619 ↗ Apr 2025 |
| Action | Inhibit | “SCO-101 is an inhibitor of ATP-Binding Cassette (ABC) efflux pumps and SRPK1 kinase which is responsible for phosphorylation of splicing factors, a key element involved in...” NCT04247256 ↗ |
| Modality | Small molecule | “SCO-101 is an oral compound that may counteract chemo-resistance by interacting with SRPK1, ABCG2 drug transporter, and liver enzyme UGT1A1.” PMID 40272619 ↗ Apr 2025 |
| Route | Oral | “Investigational Medicinal Product, oral tablet administered on day 1 to 6 (both days included) of a 14 day period.” NCT04247256 ↗ |
| Target | ABCG2 | “SCO-101 is an oral compound that may counteract chemo-resistance by interacting with SRPK1, ABCG2 drug transporter, and liver enzyme UGT1A1.” PMID 40272619 ↗ Apr 2025 |
| Target | SRPK1 | “SCO-101 is an oral compound that may counteract chemo-resistance by interacting with SRPK1, ABCG2 drug transporter, and liver enzyme UGT1A1.” PMID 40272619 ↗ Apr 2025 |
| Target | UGT1A1 | “SCO-101 is an oral compound that may counteract chemo-resistance by interacting with SRPK1, ABCG2 drug transporter, and liver enzyme UGT1A1.” PMID 40272619 ↗ Apr 2025 |